Tags

Type your tag names separated by a space and hit enter

Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses.
J Exp Med. 2020 11 02; 217(11)JE

Abstract

The emergence of SARS-CoV-2 and the ensuing explosive epidemic of COVID-19 disease has generated a need for assays to rapidly and conveniently measure the antiviral activity of SARS-CoV-2-specific antibodies. Here, we describe a collection of approaches based on SARS-CoV-2 spike-pseudotyped, single-cycle, replication-defective human immunodeficiency virus type-1 (HIV-1), and vesicular stomatitis virus (VSV), as well as a replication-competent VSV/SARS-CoV-2 chimeric virus. While each surrogate virus exhibited subtle differences in the sensitivity with which neutralizing activity was detected, the neutralizing activity of both convalescent plasma and human monoclonal antibodies measured using each virus correlated quantitatively with neutralizing activity measured using an authentic SARS-CoV-2 neutralization assay. The assays described herein are adaptable to high throughput and are useful tools in the evaluation of serologic immunity conferred by vaccination or prior SARS-CoV-2 infection, as well as the potency of convalescent plasma or human monoclonal antibodies.

Authors+Show Affiliations

Laboratory of Retrovirology, The Rockefeller University, New York, NY.Laboratory of Retrovirology, The Rockefeller University, New York, NY.Laboratory of Retrovirology, The Rockefeller University, New York, NY.Laboratory of Virology and Infectious Disease, The Rockefeller University, New York, NY.Laboratory of Virology and Infectious Disease, The Rockefeller University, New York, NY.Laboratory of Molecular Immunology, The Rockefeller University, New York, NY.Laboratory of Molecular Immunology, The Rockefeller University, New York, NY.Laboratory of Retrovirology, The Rockefeller University, New York, NY.Laboratory of Retrovirology, The Rockefeller University, New York, NY.Laboratory of Molecular Immunology, The Rockefeller University, New York, NY.Laboratory of Molecular Immunology, The Rockefeller University, New York, NY.Laboratory of Molecular Immunology, The Rockefeller University, New York, NY.Laboratory of Molecular Immunology, The Rockefeller University, New York, NY.Laboratory of Molecular Immunology, The Rockefeller University, New York, NY.Laboratory of Molecular Immunology, The Rockefeller University, New York, NY.Laboratory of Molecular Immunology, The Rockefeller University, New York, NY.Laboratory of Molecular Immunology, The Rockefeller University, New York, NY. Institute for Research in Biomedicine, Università della Svizzera italiana, Bellinzona, Switzerland.Laboratory of Molecular Immunology, The Rockefeller University, New York, NY. Howard Hughes Medical Institute, The Rockefeller University, New York, NY.Laboratory of Virology and Infectious Disease, The Rockefeller University, New York, NY.Laboratory of Retrovirology, The Rockefeller University, New York, NY.Laboratory of Retrovirology, The Rockefeller University, New York, NY. Howard Hughes Medical Institute, The Rockefeller University, New York, NY.

Pub Type(s)

Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

32692348

Citation

Schmidt, Fabian, et al. "Measuring SARS-CoV-2 Neutralizing Antibody Activity Using Pseudotyped and Chimeric Viruses." The Journal of Experimental Medicine, vol. 217, no. 11, 2020.
Schmidt F, Weisblum Y, Muecksch F, et al. Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses. J Exp Med. 2020;217(11).
Schmidt, F., Weisblum, Y., Muecksch, F., Hoffmann, H. H., Michailidis, E., Lorenzi, J. C. C., Mendoza, P., Rutkowska, M., Bednarski, E., Gaebler, C., Agudelo, M., Cho, A., Wang, Z., Gazumyan, A., Cipolla, M., Caskey, M., Robbiani, D. F., Nussenzweig, M. C., Rice, C. M., ... Bieniasz, P. D. (2020). Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses. The Journal of Experimental Medicine, 217(11). https://doi.org/10.1084/jem.20201181
Schmidt F, et al. Measuring SARS-CoV-2 Neutralizing Antibody Activity Using Pseudotyped and Chimeric Viruses. J Exp Med. 2020 11 2;217(11) PubMed PMID: 32692348.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses. AU - Schmidt,Fabian, AU - Weisblum,Yiska, AU - Muecksch,Frauke, AU - Hoffmann,Hans-Heinrich, AU - Michailidis,Eleftherios, AU - Lorenzi,Julio C C, AU - Mendoza,Pilar, AU - Rutkowska,Magdalena, AU - Bednarski,Eva, AU - Gaebler,Christian, AU - Agudelo,Marianna, AU - Cho,Alice, AU - Wang,Zijun, AU - Gazumyan,Anna, AU - Cipolla,Melissa, AU - Caskey,Marina, AU - Robbiani,Davide F, AU - Nussenzweig,Michel C, AU - Rice,Charles M, AU - Hatziioannou,Theodora, AU - Bieniasz,Paul D, PY - 2020/06/08/received PY - 2020/07/05/revised PY - 2020/07/07/accepted PY - 2020/7/22/entrez PY - 2020/7/22/pubmed PY - 2020/7/31/medline JF - The Journal of experimental medicine JO - J Exp Med VL - 217 IS - 11 N2 - The emergence of SARS-CoV-2 and the ensuing explosive epidemic of COVID-19 disease has generated a need for assays to rapidly and conveniently measure the antiviral activity of SARS-CoV-2-specific antibodies. Here, we describe a collection of approaches based on SARS-CoV-2 spike-pseudotyped, single-cycle, replication-defective human immunodeficiency virus type-1 (HIV-1), and vesicular stomatitis virus (VSV), as well as a replication-competent VSV/SARS-CoV-2 chimeric virus. While each surrogate virus exhibited subtle differences in the sensitivity with which neutralizing activity was detected, the neutralizing activity of both convalescent plasma and human monoclonal antibodies measured using each virus correlated quantitatively with neutralizing activity measured using an authentic SARS-CoV-2 neutralization assay. The assays described herein are adaptable to high throughput and are useful tools in the evaluation of serologic immunity conferred by vaccination or prior SARS-CoV-2 infection, as well as the potency of convalescent plasma or human monoclonal antibodies. SN - 1540-9538 UR - https://www.unboundmedicine.com/medline/citation/32692348/Measuring_SARS_CoV_2_neutralizing_antibody_activity_using_pseudotyped_and_chimeric_viruses_ L2 - https://rupress.org/jem/article-lookup/doi/10.1084/jem.20201181 DB - PRIME DP - Unbound Medicine ER -